Abstract
PEGylation is a common modulator of pharmacokinetics for therapeutic agents invivo. In this issue of Cell Chemical Biology, Moreno etal. (2019) show anti-PEG antibodies may directly inhibit the activity of a PEGylated aptamer, RB006, both invitro and invivo, and the issues surrounding anti-PEG antibodies are discussed.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
